Braveheart Investment notes short delay in planned testing of investee firm, Pharm 2 Farm’s anti-vir
In a statement, Braveheart said the Health and Safety Executive (HSE) and its Advisory Committee on Dangerous Pathogens, has revised the policy on working with coronavirus (SARS-CoV-2) and has scheduled an inspection at the test facility where P2F is conducting its trials.
This has had the consequential effect of delaying the trial while HSE undertake an inspection of the CL-3 laboratory to ensure all the appropriate safeguards are in place.
The laboratory is an established UK university laboratory with all the appropriate documentation in place and administered by international virology experts and Braveheart said it has been advised by P2F that it does not anticipate any problems with the inspections that would delay completion of the P2F trials beyond November 30, 2020.
The P2F team is working urgently with the University to overcome this problem but also to locate an alternative testing laboratory, if one should be required, Braveheart added.
P2F has received a conditional order for 1 million face masks per month for a period of one year from January 1, 2021. This order is subject to contract and conditional on the masks successfully completing antiviral and other performance tests and receiving the necessary PPE certifications. The order is also conditional on the buyer entering into sales contracts to sell a similar volume of masks per month.
In readiness for commercial release, Braveheart said, P2F will shortly make a patent application to protect its technology for producing the antiviral material, which it is confident could be applied to air filters, face masks and other PPE.